| DC24060 |
YM-155 hydrochloride
Featured
|
A potent, specific survivin inhibitor that inhibits survivin promoter activity with IC50 of 0.54 nM. |
|
| DC22864 |
KSP-IA |
A potent, specific, allosteric and cell-active inhibitor of KSP with IC50 of 11 nM. |
|
| DC22865 |
CK-0106023
Featured
|
A potent, specific, allosteric inhibitor of KSP motor domain ATPase with Ki of 12 nM. |
.gif)
|
| DC21318 |
ML 171 |
A potent, specific, cell-active NADPH oxidase1 (Nox1) inhibitor that strongly blocks ROS generation in HT29 cells with IC50 of 0.129 uM. |
|
| DC20890 |
ChoK-α inhibitor CK37
Featured
|
A potent, specific, competitive inhibitor of choline kinase-α (Chok-α) by targeting the choline binding site; significantly increases LC3II expression in MCF-7 and MCF-7/TAM cells, increases the size and number of autophagosome, causes MCF-7 and MCF-7/TAM |
|
| DC21110 |
HCI-2389 |
A potent, specific, irreversible NIMA-related Kinase 2 (NEK2) inhibitor with IC50 of 16.65 nM. |
|
| DC26079 |
GW 803430
Featured
|
A potent, specific, orally active melanin concentrating hormone receptor 1 (MCHR1) inhibitor with kI of 3.8 nM, >100-fold selectivity over a battery of GPCRs, ion channels and enzymes. |
|
| DC20928 |
CRT0066101
Featured
|
A potent, specific, orally active pan-PKD (protein kinase D) inhibitor with biochemical IC50 of 1, 2.5 and 2 nM for PKD1, 2, and 3 respectively. |
|
| DC22550 |
TAK-220 |
A potent, specific, orally bioavailable CCR5 antagonist that blocks the binding of MIP-1α to CCR5 with IC50 of 1.4 nM. |
|
| DC22540 |
Pasireotide
Featured
|
Pasireotide (SOM230), a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide also exhibits antisecretory, antiproliferative, and proapoptotic activity.
At equivalent molar concentrations, both the salt and free forms of a compound exhibit comparable biological activity. Nevertheless, the salt form (Pasireotide acetate) usually boasts enhanced water solubility and stability. |
|
| DC22539 |
Pasireotide L-aspartate salt |
A potent, stable cyclohexapeptide somatostatin mimic that exhibits unique high-affinity binding to human somatostatin receptors (pKi=8.2/9.0/9.1/<7.0/9.9 for sst1/2/3/4/5, respectively). |
|
| DC22746 |
TROX-1 |
A potent, state-dependent blocker of Cav2 channels that preferentially inhibits potassium-triggered calcium influx through recombinant Cav2.2 under depolarized conditions with IC50 of 0.27 uM, compared with hyperpolarized conditions (IC50>20 uM). |
|
| DC23782 |
4-Br-BnIm |
A potent, subtype-selective Grp94 inhibitor with Kd of 0.96 uM, 13-fold selectivity over Hsp90α. |
|
| DC23519 |
PF-06462894 |
A potent, subtype-selective mGluR5 negative allosteric modulator with Ki of 6.1 nM. |
|
| DC22939 |
NS3861 fumarate
Featured
|
NS3861 fumarate is an agonist of nicotinic acetylcholine receptors (nAChRs) and binds with high affinity to heteromeric α3β4 nAChR. The binding Ki values of 0.62, 25, 7.8, 55 nM for α3β4, α3β2, α4β4, α4β2, respectively. |
|
| DC22923 |
HXJ 42 |
A PP1 analog that has greater selectivity and potency for Zap-70(AS) over wild-type Zap-70, as assessed by Erk and Lat phosphorylation, as well as by proliferative responses of mature CD4+ cells. |
|
| DC22471 |
Pantoprazole sodium hydrate |
A proton pump inhibitor that inhibits gastric acid secretion. |
|
| DC23928 |
Esomeprazole magnesium salt |
A proton pump inhibitor that reduces stomach acid secretion by inhibition of the H+/K+-ATPase in the parietal cells. |
|
| DC25089 |
Esomeprazole agnesium trihydrate |
A proton pump inhibitor that reduces stomach acid secretion by inhibition of the H+/K+-ATPase in the parietal cells. |
|
| DC24176 |
Esomeprazole potassium salt |
A proton pump inhibitor that reduces stomach acid secretion by inhibition of the H+/K+-ATPase in the parietal cells. |
|
| DC23938 |
Esomeprazole sodium
Featured
|
A proton pump inhibitor that reduces stomach acid secretion by inhibition of the H+/K+-ATPase in the parietal cells. |
|
| DC23004 |
PSMA-ligand-1
Featured
|
A PSMA (prostate-specific membrane antigen) ligand-tubulysin compound.. |
|
| DC20605 |
Enexasogaol |
A pungent agent isolated from Zingiber officinale Roscoe, has been known to have anti-tumor and anti-inflammatory effects. |
|
| DC22348 |
Zalcitabine
Featured
|
A pyrimidine analog reverse transcriptase inhibitor (NRTI) for the treatment of HIV/AIDS. |
|
| DC22388 |
Mefloquine hydrochloride |
A quinoline antimalarial drug that is structurally related to the antiarrhythmic agent quinidine. |
|
| DC21407 |
AG-1295 |
A quinoxaline-type tyrphostin that acts as a potent and selective inhibitor of PDGFR kinase in vitro and in Swiss 3T3 cells with IC50 of 0.3-1 uM. |
|
| DC23472 |
TASP0434299 |
A radioligand candidate for arginine vasopressin 1B (V1B) receptor that exhibits high binding affinities for human and rat V1B receptors with IC50 of 0.526 and 0.641 nM, respectively. |
|
| DC26104 |
UVI 2008 |
A RARβ/γ agonist originated from TTNPB, is also a selective inhibitor of aldo-keto reductase family member 1B10 (AKR1B10) with IC50 of 6.1 uM. |
|
| DC22985 |
BMS-948 |
A RARβ-selective agonist that exhibits a full transcriptional agonistic activity and activating RARβ as efficiently as the reference agonist TTNPB. |
|
| DC7350 |
9-methyladenine |
A receptor adenine derivative binding membrane brain animal cell line.For the detailed information of 9-methyladenine, the solubility of 9-methyladenine in water, the solubility of 9-methyladenine in DMSO, the solubility of 9-methyladenine in PBS buffer, the animal experiment (test) of 9-methyladenine, the cell expriment (test) of 9-methyladenine, the in vivo, in vitro and clinical trial test of 9-methyladenine, the EC50, IC50,and Affinity of 9-methyladenine, Please contact DC Chemicals.. |
|
